Mereo BioPharma (MREO) Income from Continuing Operations (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Income from Continuing Operations of 6719000.0 for Q1 2026, up 47.86% year-on-year from 4544096.2 in Q1 2025, and up 62.18% on a QoQ basis from 17765000.0 in Q4 2025.
Mereo BioPharma (MREO) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Income from Continuing Operations for 4 consecutive years, with 6719000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations rose 47.86% year-over-year to 6719000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 46124000.0 (up 20.55% YoY) and the FY2025 annual result came in at 52292000.0, up 3.37% from the prior year.
- Income from Continuing Operations grew to 6719000.0 in Q1 2026 per MREO's latest filing, from 17765000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for MREO reached as high as 1751000.0 in Q2 2023 and fell as low as 17909000.0 in Q4 2024.
- A 4-year average of 10968769.23 and a median of 12076000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 599.89% — and 2025, when it surged 53.18%.
- Year by year, Income from Continuing Operations stood at 9109000.0 in 2023, then slumped by 96.61% to 17909000.0 in 2024, then gained by 0.8% to 17765000.0 in 2025, then jumped by 62.18% to 6719000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 6719000.0, 17765000.0, and 7024000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Mereo BioPharma | 232.52 Mn | 232.52 Mn | - | -6.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.72 Mn |
| Dec 31, 2025 | -17.77 Mn |
| Sep 30, 2025 | -7.02 Mn |
| Jun 30, 2025 | -14.62 Mn |
| Mar 31, 2025 | -12.89 Mn |
| Dec 31, 2024 | -17.91 Mn |
| Sep 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | -12.26 Mn |
| Mar 31, 2024 | -8.95 Mn |
| Dec 31, 2023 | -9.11 Mn |
| Sep 30, 2023 | -6.53 Mn |
| Jun 30, 2023 | -1.75 Mn |
| Mar 31, 2023 | -12.08 Mn |